Chardan Capital Initiates Coverage On Metagenomi with Buy Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits has initiated coverage on Metagenomi (NASDAQ:MGX) with a Buy rating and set a price target of $21.
March 05, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital initiated coverage on Metagenomi with a Buy rating and a price target of $21.
The initiation of coverage by Chardan Capital with a Buy rating and a significant price target suggests a positive outlook for Metagenomi's stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100